Pancreatic Cancer Research

Clinical trialObservationalUnknown

Microbial Diversity of Pancreatic Diseases

Outcome
Outcome unknown
Phase
Observational
Status
Unknown
Study type
Observational
Start
1 February 2019
Listed end
31 December 2025
Enrollment
330 participants
Sites
1
Primary outcomes
16sRNA and metagenomics
Sponsor type
Academic / other
Results posted
No
Last update
15 June 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study plans to analyze the digestive flora structure of the group of patients with pancreatic cancer. The investigators compared the microflora of pancreatic cancer with other pancreatic diseases and healthy people,in order to obtatin the information of microbial community difference among the different groups. Finally,the investigators hope to identify the potential biomarker and pathogenic mechanisms that causes the onset and progression of pancreatic diseases.

Detailed description public domain (ClinicalTrials.gov)

First, all the participants provided written informed consent for participating in the study. And the collecting procedures have no intervention or impact on treatment measures. Second,the samples are collected, including the stools, the peripheral blood, and other digestive secretions. If the participants had surgical indications and received surgical treatment, the surgical resections of tissues (including paraffin section) are also collected. Third, the participants were basically divided into three groups,cases with pancreatic cancer, cases with other pancreatic diseases, and health volunteers. Finally, the investigators compare the microflora , its metabolites or effects among the different groups in their stool, digestive secretions, peripheral blood, pancreatic tissues ( (including paraffin section)) and so on, and hope to identify the potential biomarker and pathogenic mechanisms that causes the onset and progression of pancreatic diseases.